Your PCOS May Have a Genetic Root. Here's What Your DNA Shows.

Your MTHFR gene encodes an enzyme called methylenetetrahydrofolate reductase. This enzyme converts dietary folate into methylfolate, the active form your cells use to manufacture DNA, repair DNA, and regulate gene expression. This methylation process is especially critical during ovulation, embryo development, and early pregnancy when cells are dividing rapidly and genetic material must be precisely copied.

The most common variant is the C677T substitution, carried by roughly 40% of people with European ancestry. Individuals with two copies of the T variant have an enzyme that works at only 30-40% of normal efficiency. Even one copy reduces activity by roughly 20-30%. The result: your cells cannot produce methylfolate quickly enough to meet the high demand during ovulation and early embryo development.

For women with PCOS, MTHFR variants amplify several problems. Impaired methylation worsens insulin sensitivity, increases homocysteine (which damages ovarian blood vessels), and compromises ovum quality. If you proceed to IVF, poor methylation capacity can worsen embryo development, increase miscarriage risk, and reduce implantation rates. You may feel that you are on a fertility plateau: your ovaries produce eggs, but the eggs do not fertilize well or the embryos do not develop normally.

Your FSHR gene codes for the FSH receptor, a protein sitting on the surface of ovarian cells that receives the signal from follicle-stimulating hormone (FSH). When FSH binds to this receptor, your ovary responds by growing follicles and maturing eggs. The strength of this receptor determines how sensitive your ovaries are to FSH stimulation.

The most significant variant is the N680S polymorphism (rs6166). Women carrying the S/S genotype, present in roughly 10-15% of the population, have FSH receptors that are less sensitive to the hormone’s signal. This means your ovaries require higher FSH levels to trigger follicle growth. At normal FSH concentrations, your ovarian response is muted. If you are trying to conceive naturally, you may have lower ovarian reserve or delayed ovulation. If you proceed to IVF, your ovaries may respond poorly to standard stimulation doses, yielding fewer eggs or requiring much higher medication doses.

Women with PCOS and FSHR S/S variants often report a frustrating pattern: they ovulate irregularly or not at all on their own, and they do not respond well to standard IVF stimulation protocols. They feel trapped between two realities: not enough FSH signal to ovulate naturally, and suboptimal ovarian reserve relative to their age.

Your ESR1 gene codes for the estrogen receptor alpha, the primary receptor through which estrogen exerts its effects on reproductive tissues. This receptor sits on cells lining your endometrium (uterine lining), your ovaries, and your fallopian tubes. How well these receptors bind estrogen determines how sensitively your endometrium responds to estrogen signaling, which is critical for endometrial thickening, receptivity to implantation, and successful pregnancy establishment.

The most studied variants are the PvuII and XbaI polymorphisms. Roughly 40% of women carry at least one variant copy. Women with certain ESR1 variant combinations have reduced endometrial sensitivity to estrogen, meaning their uterine lining may not thicken adequately or may not achieve optimal receptivity during the implantation window. This is especially problematic in PCOS, where hormonal dysregulation already stresses the endometrium.

You may experience this as poor endometrial development in natural cycles or suboptimal endometrial thickness despite high estrogen levels in IVF cycles. Embryos may fail to implant even when they are genetically normal. Blood tests show your estrogen is adequate. Ultrasound shows your endometrium is adequate by thickness measurements. Yet implantation fails repeatedly. ESR1 variants are a hidden cause of recurrent implantation failure.

Your CFTR gene codes for the cystic fibrosis transmembrane conductance regulator, a protein that manages chloride and water transport across cell membranes. In the reproductive tract, CFTR regulates the viscosity and composition of reproductive mucus and the secretions in the vas deferens (in males) and fallopian tubes (in females). Proper CFTR function ensures that reproductive secretions are thin enough to allow sperm transport and that the reproductive ducts develop normally.

While full cystic fibrosis requires two disease-causing CFTR mutations, carrier variants of CFTR are extremely common, occurring in roughly 1 in 25 people of European ancestry. CFTR carriers typically have no respiratory symptoms but may have subtle reproductive consequences. In females, CFTR variants can slightly increase mucus viscosity or alter ductal secretions, subtly impairing sperm survival or egg retrieval. In males, CFTR variants are the leading genetic cause of congenital bilateral absence of the vas deferens (CBAVD), a condition causing obstructive azoospermia (no sperm in ejaculate despite normal testicular sperm production).

For women with PCOS who also carry CFTR variants, the reproductive impact is typically mild unless the partner has male factor infertility. If your partner is a CFTR carrier or has unexplained low sperm count, CFTR variants become relevant for your reproductive planning, particularly if you are considering IVF or IUI.

Your DAZL gene (Deleted in Azoospermia-Like) sits on the Y chromosome and encodes a protein essential for spermatogenesis, the process of sperm cell production. DAZL works alongside other Y-chromosome genes to ensure that sperm cells develop normally from immature germ cells. Without functional DAZL, spermatogenesis stalls and sperm production fails.

Deletions in the DAZL region (part of the AZFc region of the Y chromosome) occur in roughly 1 in 2,000 to 3,000 men with infertility but are almost never found in men with normal fertility. Men with DAZL deletions typically have azoospermia (zero sperm count) or severe oligospermia (extremely low sperm count). This is not a condition that improves with lifestyle changes, supplements, or time. It requires assisted reproductive technology such as IVF with testicular sperm extraction (TESE) or microdissection TESE (microTESE).

If you are a woman with PCOS whose partner has low or absent sperm count, DAZL testing can clarify whether his infertility stems from a specific genetic deletion or from modifiable causes like varicocele, hormonal imbalance, or environmental toxin exposure. This distinction fundamentally changes your reproductive options and timeline.

Your AR gene codes for the androgen receptor, a protein that receives testosterone and DHT (dihydrotestosterone) signals in cells throughout your body, including your testes, prostate, and reproductive tract. The androgen receptor is critical for male sexual development, sperm production, and maintaining muscle mass and bone density. How sensitively cells respond to testosterone depends partly on the structure of the androgen receptor protein, which is determined by a variable-length stretch of CAG repeats in the AR gene.

The CAG repeat length is highly variable, ranging from roughly 8 to 35 repeats. Men with shorter CAG repeats (fewer repeats) have more sensitive androgen receptors and respond more strongly to testosterone. Men with longer CAG repeats (more repeats) have less sensitive receptors and require higher testosterone levels to achieve the same biological effect. The population average is roughly 21 repeats, and variants with 24 or more repeats are considered “long.”

In males, longer CAG repeats are associated with lower testosterone responsiveness, which can reduce sperm production and increase infertility risk. Some studies show that men with very long CAG repeats (30+) have lower sperm counts and higher infertility rates. If you are a woman with PCOS whose partner has borderline low testosterone or low-normal sperm count, AR CAG repeat length may help explain whether his fertility issues stem from androgen receptor insensitivity or from true testosterone deficiency.